Correlation between pituitary growth hormone reserve and degree of growth failure in children with short stature

1988 ◽  
Vol 147 (6) ◽  
pp. 584-587 ◽  
Author(s):  
S. Kajiwara ◽  
N. Igarashi ◽  
E. Imura ◽  
T. Sato
2015 ◽  
Vol 2015 ◽  
pp. 1-4 ◽  
Author(s):  
Susan R. Mendley ◽  
Fotios Spyropoulos ◽  
Debra R. Counts

We describe an alternative strategy for management of severe growth failure in a 14-year-old child who presented with advanced chronic kidney disease close to puberty. The patient was initially treated with growth hormone for a year until kidney transplantation, followed immediately by a year-long course of an aromatase inhibitor, anastrozole, to prevent epiphyseal fusion and prolong the period of linear growth. Outcome was excellent, with successful transplant and anticipated complete correction of height deficit. This strategy may be appropriate for children with chronic kidney disease and short stature who are in puberty.


2018 ◽  
Vol 7 (10) ◽  
pp. 1096-1104 ◽  
Author(s):  
Robert Rapaport ◽  
Peter A Lee ◽  
Judith L Ross ◽  
Paul Saenger ◽  
Vlady Ostrow ◽  
...  

Growth hormone (GH) is used to treat short stature and growth failure associated with growth disorders. Birth size and GH status variably modulate response to GH therapy. The aim of this study was to determine the effect of birth size on response to GH therapy, and to determine the impact of GH status in patients born small for gestational age (SGA) on response to GH therapy. Data from the prospective, non-interventional American Norditropin Studies: Web-Enabled Research (ANSWER) Program was analyzed for several growth outcomes in response to GH therapy over 3 years. GH-naïve children from the ANSWER Program were included in this analysis: SGA with peak GH ≥10 ng/mL (20 mIU/L), SGA with peak GH <10 ng/mL (20 mIU/L), isolated growth hormone deficiency (IGHD) born SGA, IGHD not born SGA and idiopathic short stature. For patients with IGHD, those who did not meet criteria for SGA at birth showed greater improvements in height SDS and BMI SDS than patients with IGHD who met criteria for SGA at birth. For patients born SGA, response to GH therapy varied with GH status. Therefore, unlike previous guidelines, we recommend that GH status be established in patients born SGA to optimize GH therapy.


Author(s):  
Nicholas Krasnow ◽  
Bradley Pogostin ◽  
James Haigney ◽  
Brittany Groh ◽  
Winston Weiler ◽  
...  

AbstractBackgroundPituitary cysts have been speculated to cause endocrinopathies. We sought to describe the prevalence and volumetry of pituitary cysts in patients with growth hormone deficiency (GHD) and idiopathic short stature (ISS).MethodsSix hundred and eighteen children evaluated for growth failure at the Division of Pediatric Endocrinology at New York Medical College between the years 2002 and 2012, who underwent GH stimulation testing and had a brain magnetic resonance imaging (MRI) prior to initiating GH treatment were randomly selected to be a part of this study. High resolution MRI was used to evaluate the pituitary gland for size and the presence of a cyst. Cyst prevalence, cyst volume and percentage of the gland occupied by the cyst (POGO) were documented.ResultsFifty-six patients had a cyst, giving an overall prevalence of 9.1%. The prevalence of cysts in GHD patients compared to ISS patients was not significant (13.5% vs. 5.7%, p=0.46). Mean cyst volume was greater in GHD patients than ISS patients (62.0 mm3vs. 29.4 mm3, p=0.01). POGO for GHD patients was significantly greater (p=0.003) than for ISS patients (15.3%±12.8 vs. 7.1%±8.0). Observers were blinded to patient groups.ConclusionsGHD patients had a significantly greater volume and POGO compared to ISS patients. This raises the question of whether cysts are implicated in the pathology of growth failure.


1997 ◽  
Vol 48 (4) ◽  
pp. 19-22 ◽  
Author(s):  
C.L. Boguszewski ◽  
B. Carlsson ◽  
L.M.S. Carlsson

Author(s):  
Thomas Edouard ◽  
Maïthé Tauber

Short stature (SS) is defined as height less than the third percentile or below –2 standard deviation score (SDS) with reference to chronological age according to standard growth curves. Children are born small for gestational age (SGA) when their birth height and/or birth weight are below or equal to –2 SDS using standards such as Usher and McLean. In patients presenting with SS associated with abnormal physical features, malformations, or delayed development, a syndromic growth disorder should be considered. Whilst individually rare, there are many syndromes with short stature as a component—in the London Dysmorphology Database (Winter and Baraitser), there are 873 such syndromes, 175 of which are of prenatal onset. In these patients, malformations and/or sensorineural abnormalities should be systematically screened by complementary exams (skeletal X-rays, cardiac and abdominal ultrasound, complete eye and hearing evaluations). In some cases, these abnormalities could help in making the diagnosis (e.g. pulmonary stenosis suggestive of Noonan’s syndrome). Different chromosome disorders may present with SS. For this reason, chromosome studies, preferably high-resolution analysis, should be performed to search for chromosome abnormalities in these children. Specific gene analysis may be requested when a specific syndrome is suspected. In these syndromes, growth failure may be due to a wide variety of mechanisms, including growth hormone deficiency (GHD), growth hormone resistance (Laron syndrome, bone dysplasia) or in combination with nutritional issues with, in many, the underlying mechanisms still being unknown. A complete evaluation of growth hormone/IGF-1 axis is necessary in these children. There are many classifications of short stature, each with specific advantages and disadvantages. Indeed, syndromes with SS could be classified according to clinical presentation and in particular auxological and anthropometrical parameters (SS with normal prenatal growth, SS with intrauterine growth retardation, SS with obesity), or to pathophysiology (GHD or growth hormone insensitivity, bone disorders and idiopathic SS). Here, a classification based on clinical presentation is used. Those syndromes with SS that are most common and are often followed by paediatric endocrinologists namely Silver–Russell, Noonan’s, Turner’s and Prader–Willi syndromes will be reviewed, as well as some rarer syndromes.


Author(s):  
L. Patel ◽  
P. E. Clayton

Reduced height velocity for age and stage of puberty implies slow growth. Although this occurs independently from actual height, children identified for investigation tend to be the ones who are slowly growing, as well as short. The majority of short slowly growing children do not have a recognized endocrinopathy. The commonest growth disorders are those grouped under the heading ‘idiopathic’, which includes constitutional delay in growth and puberty, a disorder of the tempo of maturation, and familial/genetic short stature. These children present with short stature, an unremarkable phenotype, and a variable extent of growth failure. The challenge to the clinician is to differentiate these children from those who may have a defined nonendocrine pathology (for example, chronic systemic disease (Box 7.2.4.1), bone disorder, or psychosocial problem) and those who may have an abnormality within the growth hormone axis.


Author(s):  
Ljiljana Šaranac

Short stature is the most visible and prominent physical characteristic and one of the commonest reason for referral to pediatric endocrinologist. It is assumed as disabling condition with psychosocial consequences that seeks treatment. Behind short stature severe pathology could be hidden, although not necessarily of endocrine origin. Even in the new millennium, many diagnostic pitfalls and dilemmas persist in confirmation of growth hormone deficiency (GHD), the first indication that fits in endocrine paradigm: to replace the missing hormone. In 1985 FDA approved recombinant human GH (hGH) as the treatment of pediatric patients who have growth failure due to inadequate secretion of endogenous GH. Availability of hGH in unlimited amounts enhanced the number of indications of GH use. Pediatric endocrinologist started to promote and to apply use of hGH for height in short, but otherwise healthy children, with hormonal normalcy. Reasonable criticism of such praxis arises in the light of recent safety alerts. The unbearable lightness of prescribing growth hormone to every apparently or really short child is reaching epidemic progress in Serbia. When authorities in this low income country (estimated as developing), approved hGH for use in SGA (small for gestational age) children, use and misuse of hGH exploded. Socially acceptable height, the term applied by some endocrinologists actually means that society does not accept short people. The pharmaceutical companies go even further offering, besides growth acceleration, better and brighter future for potential patients, in whom the self-confidence is measured by centimeters of height. However, benefits of such treatment on quality of life were never confirmed. Children with severe growth failure and documented GHD should be treated undoubtedly, but use of hGH for height, so called cosmetic endocrinology, needs critical appraisal. Children and their parents should be informed about height prediction and long-term consequences.


2021 ◽  
Author(s):  
Willem Staels ◽  
Nuriya Alev ◽  
Isabelle Maystadt ◽  
Olimpia Chivu ◽  
Jean De Schepper ◽  
...  

Context: Short stature in children is a common reason for referral to pediatric endocrinologists. The underlying cause of short stature remains unclear in many cases and patients often receive unsatisfactory, descriptive diagnoses. While textbooks underline the rarity of genetic causes of growth hormone (GH) insensitivity and the severity of its associated growth failure, increased genetic testing in patients with short stature of unclear origin has revealed gene defects in the GH/ insulin-like growth factor (IGF-I) axis associated with milder phenotypes. As such, heterozygous IGF1 gene defects have been reported as a cause of mild and severe short stature. Here, we aimed to describe the clinical and hormonal profile of children with IGF1 haploinsufficiency and their short-term response to growth hormone treatment (GHT). Case descriptions: We describe five patients presenting with short stature, microcephaly, and in 4 out of 5 born small for gestational age diagnosed with IGF1 haploinsufficiency. The phenotype of these patients resembles that of previously described cases with similar gene defects. In our series, segregation of the short stature with the IGF1 deletion is evident from the pedigrees and our data suggests a modest response to GHT. Conclusions: This study is the first case series of complete heterozygous IGF1 deletions in children. The specific genetic defects provide a clear image of the phenotype of IGF1 haploinsufficiency - unbiased by heterozygous mutations with possible dominant negative effects on IGF-I function. We increase the evidence for IGF1 haploinsufficiency as a cause of short stature, microcephaly, and SGA.


Sign in / Sign up

Export Citation Format

Share Document